The National Cancer Institute Comparative Brain Tumor Consortium, Patient Outcomes Working Group, propose a consensus document in support of standardized magnetic resonance imaging protocols for canine brain tumor clinical trials. The intent of this manuscript is to address the widely acknowledged need to ensure canine brain tumor imaging protocols are relevant and have sufficient equivalency to translate to human studies such that: (1) multi-institutional studies can be performed with minimal inter-institutional variation, and (2) imaging protocols are consistent with human consensus recommendations to permit reliable translation of imaging data to human clinical trials. Consensus recommendations include pre-and postcontrast three-dimensional T1-weighted images, T2-weighted turbo spin echo in all three planes, T2*-weighted gradient recalled echo, T2-weighted fluid attenuated inversion recovery, and diffusion weighted imaging/diffusion tensor imaging in transverse plane; field of view of ≤150 mm; slice thickness of ≤2 mm, matrix ≥ 256 for two-dimensional images, and 150 or 256 for three-dimensional images.
INTRODUCTION
The National Cancer Institute's Comparative Brain Tumor Consortium was formed in September 2015, to collectively enhance cooperation among and collaboration between human and veterinary medical professionals and researchers involved in neurooncologic research. 1 This Consortium's overarching mission is to improve the quality and forward progress of brain tumor research by leveraging the study of spontaneous brain tumors in pet dogs, and is an extension of the National Cancer Institute's Comparative Oncology Program, which has led the field of comparative oncology research for over a decade.
There is substantial evidence that the study of naturally occurring cancers in dogs can meaningfully contribute to many fields of cancer research, including neurooncology, as tumor-bearing pet dogs are a disease model that complements knowledge gained in mouse models and through human clinical research. [2] [3] [4] Within the Comparative Brain Tumor Consortium, five distinct working groups were formed to facilitate cross-discipline communications and generate new knowledge in the following areas: tumor biology, clinical trials, drug development, pathology and molecular markers, and patient outcomes. 1 One specific goal of the Comparative Brain Tumor Consortium is to propose best practice guidelines for the conduct of multicenter clinical Vet Radiol Ultrasound. 2018;59:261-271.
c 2018 American College of Veterinary Radiology 261 wileyonlinelibrary.com/journal/vru trials that evaluate novel drugs, devices, or imaging agents in canine brain tumor patients. These trials are designed to advance diagnostic or therapeutic strategies for humans, but also serve to enhance and expand our collective understanding of canine brain tumor biology. It is generally accepted that harmonized data capture protocols assure consistency and quality of the data generated therein, which is critical to increasing the likelihood of acceptance of comparative data by stakeholders in all facets of cancer research.
Members of the Comparative Brain Tumor Consortium patient outcomes working group proposed a consensus document in support of standardized magnetic resonance imaging (MRI) protocols for canine brain tumor clinical trials. This concept is derived from a similar consensus statement for human brain tumor trials. 5 The proven benefit of using standardized imaging protocols has been realized in the Alzheimer's Disease Neuroimaging Initiative consensus as well as other initiatives. 6, 7 The intent of this manuscript is to offer initial con- For veterinary patients with brain tumors, overall survival, disease free interval, progression free survival, quality of life measures, and tumor responses can be difficult to measure and are potentially complicated by owners' discretionary resources and option of humane euthanasia in light of a brain tumor diagnosis. The assessment of tumor responses based on imaging data has become a standard surrogate for evaluating effectiveness of treatment in human neurooncology, and should be a useful tool in veterinary clinical studies as well. Indeed, MRIbased neuroimaging response criteria that describe various methods and associated challenges for measurement of tumor size and distinction from adjacent tissues have recently been described for canine brain tumor patients. 8 Standardization of techniques used for capturing, reporting, and analysis of data gathered from cooperative groups is critical for maintaining quality of such findings. Specific to imaging trials, harmonization of image acquisition parameters has been specified as a key component of successful multi-site collaboration. 9 These proposed consensus technique recommendations herein are not intended to be prescriptive, but rather provide a starting point from which minimum standards for consistent and functionally equivalent output can be achieved. It was also our intent to describe how these imaging standards could be applied throughout the conduct of a multicenter clinical trial that may evaluate a variety of therapeutic interventions. Indeed, harmonization standards for MRI-based characterization of epilepsy, based upon a parallel initiative in humans, have been provided to the veterinary community. 10 Specific to oncology, standardized metrics for characterization and attribution of adverse events that occur during therapeutic trials, as well as for assessment of response to therapy in solid tumors and lymphomas, have been widely accepted and continue to play a key role in the acceptance of such data by the cancer drug development community. [11] [12] [13] We believe that these proposed recommendations should be revisited regularly and revised accordingly as developments in technology, expertise, and knowledge occur. Successful application of the imaging guidelines proposed herein will guide and strengthen the validation and ongoing inclusion of the canine brain tumor model for human brain tumor research, and that these guidelines should continue to be modified and strengthened as knowledge and experience develops in the coming years, and as feedback is gathered and reviewed from veterinary instituitions whom choose to adopt these standards.
RECOMMENDED MAGNETIC RESONANCE IMAGING ACQUISITION AND OUTPUT PARAMETERS
Minimum hardware requirements to achieve the recommended output parameters generally require 1.5T field strength or higher. In some cases, <1.5T systems may be utilized if the images are functionally equivalent in terms of output (e.g., voxel size, field-of-view, matrix, and signal-to-noise ratio); however, in most cases the longer scan times preclude feasibility of achieving these output parameters with lower field magnets. Regardless, the recommendations presented here are output-based to accommodate variations in hardware. Where vendorspecific sequence terminology is used, equivalent terminology and sequences may be available from other vendors.
Recommended sequence protocols should include, at a minimum, pre-and postcontrast three-dimensional T1-weighted images, T2-weighted turbo spin echo (TSE) in all three planes, T2*-weighted gradient recalled echo, T2-weighted fluid attenuated inversion recovery (FLAIR), and diffusion weighted imaging/diffusion tensor imaging in transverse plane ( Table 1 ). The rationale for these sequences is described in more detail below, with consideration of relevant veterinary-specific MRI literature. [14] [15] [16] [17] [18] To maximize scanning efficiency, recommendations as to the order of scanning are presented in Table 1 and described later in the text.
Output parameters
A field of view of ≤150 mm is recommended in all three planes for both two-dimensional and three-dimensional images. Three-dimensional T1-weighted images should have isotropic voxels ≤1 mm, with no gap and no overlap. Slice thickness should be ≤3 mm for two-dimensional brain images, with 2 mm considered ideal. Matrix size should be ≥256 c Limited dog-specific data are available. These parameters are based upon human recommendations. 5 Multi shot EPI and spin echo sequences employing a radial acquisition scheme may be considered as alternatives.
for two-dimensional brain images. Provided the field of view is 150 mm, these parameters would create voxels that are no larger than 0.58 × 0.58 × 3 mm for two-dimensional images, and either 0.6 mm (if matrix is 256 mm) or 1 mm (if matrix is 150 mm) isotropic voxels for threedimensional images.
The ideal MRI slice thickness in dogs has not been determined, although it is thought that thinner slices with no spacing allows for better tumor delineation. Since the canine brain is smaller than the human brain, the recommended minimum MRI slice thickness in dogs is thinner than recommended for humans. In human patients, the Response Assessment in Neuro-Oncology criteria recommend a minimum MRI slice thickness of 5 mm with no interslice spacing for evaluation. 19 In order to reduce volume averaging, a slice thickness of ≤2 mm is recommended as ideal for canine subjects.
Effect of field strength
In general, higher field strength results in improved spatial resolution, contrast-to-noise ratio, and signal-to-noise ratio relative to scan time. [20] [21] [22] Theoretically, this should result in improved lesion margin delineation and conspicuity. That being said, rigorous studies comparing field strength within canine subjects with brain tumors have not been performed, and studies in human subjects with brain tumors focused largely on contrast enhancement relative to field strength, rather than noncontrast sequences. [20] [21] [22] When planning multicenter studies involving different field strengths, it is important that certain differences are considered, aside from tumor delineation. For example, certain artifacts, such as chemical shift and magnetic susceptibility artifact, can be more problematic at higher fields, such as 3T. 23, 24 Although compensation can be achieved by increasing bandwidth, this in turn affects signal-to-noise ratios. Such differences as a result of field strength and limitations must be considered in multi-institutional trials.
T2-weighted sequences
T2-weighted TSE sequences should be acquired in all three planes. T2-weighted sagittal and dorsal images are generally acquired earlier in the scanning protocol to permit rapid assessment of anatomic structures. Similar to the human consensus recommendations, T2-weighted transverse sequences may be acquired after gadolinium administration to standardize the timing of postcontrast T1-weighted image acquisition and to maximize efficiency by actively scanning during the delay after contrast administration. Although gadolinium can effect T2-weighted imaging, the effects are minimal at clinically relevant gadolinium concentrations and time of echo. As such, for T2-weighted images, performing the T2-weighted acquisition after gadolinium administration should have no effect on image integrity.
T2-weighted flame-attenuated inversion recovery sequences
T2-weighted FLAIR sequences should be acquired as part of the minimum acquisition for brain tumor clinical trials. The T2-weighted FLAIR sequence is recommended primarily to aid in lesion assessment adjacent to cerebral spinal fluid-filled structures. Importantly, many canine gliomas share a margin with the ventricles and are difficult to fully delineate on T2-weighted images made without inversion recovery. 25 
T2*-weighted sequences
Even though the human recommendations do not include a T2*-weighted sequence, we chose to include this in the canine recommendations for two reasons. First, imaging findings in dogs with hemorrhagic infarcts can overlap with those of neoplasia. 17, 26 In longitudinal studies, it may be important to recognize changes in lesion size caused by intratumoral or peritumoral hemorrhage that may be related to interventions included within the clinical trial schema.
Three-dimensional T1-weighted sequences
When possible, the centers participating in the clinical trial should perform three-dimensional T1-weighted sequences that are similar with respect to pulse sequence type (gradient echo or spin echo), field-ofview, and image contrast. [27] [28] [29] [30] We recommend chemical fat saturation in order to improve sensitivity for the detection of gadolinium contrast medium. 31 There are several advantages of three-dimensional sequences over standard two-dimensional sequences. For example, images acquired in three dimensions can be reconstructed in the transverse, sagittal, and dorsal plane with reduced acquisition time compared to acquiring two-dimensional images in all three planes. Furthermore, tumor volume estimation utilizing three-dimensional sequences is more straightforward because of the isotropic voxels, lack of interslice gaps, and reduced partial volume effects. These observations are reiterated in published human and veterinary literature, specifically with respect to the significant variability in one-and two-dimensional measurements due in large part to variation in slice location between serial scans. [32] [33] [34] While two-dimensional spin echo imaging may produce images with increased conspicuity of contrast medium, three-dimensional imaging performs similarly in lesion detection and may depict nonenhancing tumors better. 35, 36 Comparing three-dimensional TSE and gradient echo sequences at 3T, the TSE images have the advantage of reduced vascular signals (which could mimic neoplasia) while gradient echo images have superior gray/white matter distinction. 37 
Diffusion-weighted sequences
Diffusion weighted imaging or diffusion tensor imaging is recommended for several reasons. First, may aid in the differentiation of dogs with neoplasia from those with ischemic infarcts. 38 
Contrast imaging
Dosing and timing of contrast-medium administration prior to image acquisition should be standardized for the study protocol as well as across multiple sites. Normal contrast enhancement of the choroid plexus, meningeal blood vessels and nasal mucosa should be readily apparent on each study. Where possible, the use of subtraction images to evaluate contrast-enhancement is recommended. [45] [46] [47] [48] [49] Performing comparable T1-weighted sequences both pre-and postcontrast permits the use of subtraction images to evaluate contrast enhancement, which can be performed automatically on most proprietary and open source commercial image analysis platforms and does not require sequential imaging. However, if pre-and post-gadolinium images are acquired sequentially as a dynamic sequence, T2-weighted images cannot be acquired in the interim. 49 There is evidence in the literature that subtraction scans are superior for monitoring tumor progression. 48 The optimal duration between contrast medium injection and imaging is not known. That being said, a delay of at least 5 min seems to be beneficial and prolonged delays have not resulted in improved characterization of meningeal enhancement in dogs. 31, 47 
Image processing and reporting
All studies must be DICOM-send compliant to permit multiinstitutional transfer for image review and analysis. Clinical trial centers should consider whether a central read at a designated site and/or with a blinded review is required to avoid interobserver variation or bias. Where a central read is not standard for a multiinstitutional trial, minimum standards for reporting elements should be shared across all participating sites.
GUIDELINES ON IMPLEMENTATION OF STANDARDIZED MAGNETIC RESONANCE IMAGING PROTOCOLS

High-level considerations and compromises
This manuscript is meant to provide a framework for brain tumor clinical trials that include MRI to support the consistent, clear, and reproducible methodology that should be considered the minimum standard for conductance of such comparative canine trials moving forward. While we collectively acknowledge the variability in hardware and software between sites, we similarly acknowledge the need for prospective determination of imaging protocol prior to initiation of the trial among the participating investigators. We envision a pragmatic approach wherein a realistic balance can be struck between an ideal scenario involving high-performance systems that may not ods are yet to be standardized and include using varying software packages. 58 There is some information in the veterinary literature on the assessment of serial images to determine brain tumor treatment response and no widely agreed-upon methods have been published to date, although several studies have used published human criteria. 8, 59 The reader is directed to a previous publication that compares and contrasts RECIST, Macdonald, Response Assessment in Neuro-Oncology, and volumetric methods (Table 3) . 8 
Interobserver variability
To limit measurement variability within a study the same DICOM viewing software and the same observer should evaluate each image set within a study even for multi-institutional studies. The use of multiple observers taking the same measurement independently to limit and assess interobserver effects should be considered.
Baseline imaging prior to enrollment into a clinical trial
To avoid significant alterations in the tumor or peritumoral environments between the time of imaging diagnosis and any intended inter- 
Serial imaging
Serial imaging should be done using the same pulse sequence parameters, slice thickness, the same dose and type of contrast medium, and the same duration between contrast medium administration and imaging. Consistency in these factors is important, as minor differences in protocol parameters or hardware result in significant differences in image output, as described elsewhere in this text.
For now, adoption of the human Response Assessment in Neuro-Oncology criteria, which can be readily applied to other tumor types, should be considered. Alternatively, other three-dimensional volumetric methods can be used in addition with appropriate reporting of the imaging and methodology used so they can be repeated by other groups until such time as there is consensus on the use of these methods.
Timing of magnetic resonance imaging
Given the current knowledge gaps regarding the natural history of disease and the lack of evidence-based, standard-of-care therapies for spontaneous brain tumors in companion animals, the ideal intervals for the performance of MRI surveillance are largely unknown. 65, 66 The human neurooncology experience with development and incorporation of imaging-based therapeutic response assessments into brain clinical trials has demonstrated that all aspects of the process require continual adaptation and evolution in response to new discoveries and technologies. 67, 68 Thus, while the optimization of the timing of posttreatment imaging in veterinary medicine will be dependent on factors including tumor histology and grade, the anticipated therapeutic and adverse effects of the treatment administered, the patient's clinical status, and the defined end-points of each clinical trial, these recommendations should remain subject to change as our understanding of brain tumors progresses. Additional considerations include expected responses and outcomes to limit loss of data points, and treatment interventions that may result in either pseudoresponses or pseudoprogression. In animals with spontaneous brain tumors, an additional practical consideration regarding the scheduled frequency of posttreatment MRI surveillance is the necessity to anesthetize patients in order to obtain diagnostic datasets. 8, 65, 66 There are several issues that confound extraction of evidenced- palliatively, and thus minimizes attrition due to death or euthanasia prior to obtaining posttreatment imaging. 8, 70 Accounting for these factors and complexities, Table 2 summarizes the recommendations for timing of imaging for 3T and <3T MRI units.
Early postoperative imaging
In humans, surgery is a primary therapeutic modality for brain tumors, and is often the only treatment used for low-grade tumors. Given the established and emerging prognostic importance of the extent of regions of enhancement conforming to the margins of the resection bed or regional meninges. 83, 84 Studies describing posttreatment imaging following radiothera- 
Adjunctive patient outcome assessments
Postmortem evaluation of all deceased subjects should be included as a goal in all prospective veterinary trials to allow for assessment of histology, tumor response, and any associated toxicity. This is especially important in veterinary neurooncology studies where preintervention histopathology may not be available and the tumor diagnosis may be based on imaging criteria.
CONCLUSIONS
In summary, authors of this commentary review believe that prospectively defining image acquisition and reporting criteria is essential to maximize the value of veterinary neurooncology studies, and that these guidelines reflect a starting point for minimum standards that could lead to greater cooperation among the brain tumor research community and acceptance of canine patient as a translationally relevant model for humans. Where available, the human Response Assessment in Neuro-Oncology criteria based on the tumor histology being studied should be applied as a response criteria in veterinary studies. Until such time that the Response Assessment in Neuro-Oncology criteria for meningiomas is developed, the Response Assessment in Neuro-Oncology criteria for high grade gliomas can be used to evaluate a response to therapy. The response and reporting criteria being recommended in this document are designed to limit variability both within and between studies and provide more robust data for veterinary observational and clinical trials. This is proposed as a working document. These guidelines should continue to be modified and strengthened as evidence-based knowledge and experience develop in the coming years, and be revised accordingly as developments in technology, expertise, and knowledge occur.
As a number of equipment vendors exist currently, and as we cannot foresee what imaging technology will be emerging in the future, the consensus recommendations contained in this paper represent minimum output standards to permit functional equivalency for sites participating in multicenter canine brain tumor clinical trials. These recommendations are not meant to limit those sites that wish to surpass these minimum standards. The intended use of these recommendations is simply to support multiinstitutional collaborations and more relevant comparisons to other studies. Further, it is worth considering adopting these as minimum standards in any patient with an intracranial localization, such that if a brain tumor is found, the images would permit post-hoc entry into a clinical trial.
